Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Shadow pricing and the art of profiteering from outdated therapies

An Author Correction to this article was published on 01 November 2019

This article has been updated

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: ‘Shadow pricing’ between Lantus and Levemir from 2015 to 2016.

Bloomberg Intelligence Analysis of Data retrieved from Symphony Health Solutions.

Change history

  • 01 November 2019

    An amendment to this paper has been published and can be accessed via a link at the top of the paper.


  1. 1.

    Pharmaceutical Research and Manufacturers of America (PhRMA). Prescription medicines: costs in context. Advocacy: Cost & Value of Medicines (2016).

  2. 2.

    Greenwood, J. U.S. drug costs must be weighed against benefits. Bloomberg News (2015).

  3. 3.

    Scannell, J. W., Blanckley, A., Boldon, H. & Warrington, B. Nat. Rev. Drug Discov. 11, 191–200 (2012).

    CAS  Article  Google Scholar 

  4. 4.

    Brennan, Z. Congressmen investigate ‘shadow pricing’ of MS drugs. Regulatory Focus (2017).

  5. 5.

    Kelley, T. U.S. insulin prices rise as Sanofi, Novo await rivals. Bloomberg News (2013).

  6. 6.

    Langreth, R. Hot drugs show sharp price hikes in shadow market. Bloomberg News (2015).

  7. 7.

    Barrett, P. & Langreth, R. The crazy math behind drug prices. Bloomberg Businessweek (2017).

  8. 8.

    Persistence Market Research. Biosimilar Market: Pricing Analysis 2006–2017 (Persistence Market Research, New York, 2017).

    Google Scholar 

  9. 9.

    Hartung, D. M., Bourdette, D. N., Ahmed, S. M. & Whitham, R. H. Neurology 84, 2185–2192 (2015).

    Article  Google Scholar 

  10. 10.

    Benmeleh, Y. FDA deals blow to Teva’s defense plan with ruling on Bendeka. Bloomberg News (2016).

  11. 11.

    Serebrov, M. PBMs: The ‘shadow’ players in the drug pricing skirmish? BioWorld (2016).

  12. 12.

    Tufts Center for the Study of Drug Development (CSDD). Cost of Developing a New Drug (Tufts CSDD, Boston, 2014).

  13. 13.

    Loftus, P. U.S. investigates drugmaker contracts with pharmacy-benefit managers. The Wall Street Journal (2016).

  14. 14.

    Wingfield, N., Thomas, K. & Abelson, R. Amazon, Berkshire Hathaway and JPMorgan team up to try to disrupt health care. The New York Times (2018).

Download references

Author information



Corresponding author

Correspondence to Anurag S Rathore.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Rathore, A.S., Shereef, F. Shadow pricing and the art of profiteering from outdated therapies. Nat Biotechnol 37, 217–220 (2019).

Download citation

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing